Bajaj Healthcare Limited Approves FY Results and Recommends Final Dividend
Bajaj Healthcare Limited announced the outcomes of its Board Meeting held on May 8, 2026, detailing the approved audited standalone financial results for the quarter and financial year ended March 31, 2026. The Board also recommended a final dividend for the previous fiscal year and appointed external auditors for the 2026-27 period.The Board considered and approved the company's audited standalone financial results for the quarter and financial year ended March 31, 2026. Additionally, the directors recommended a final dividend at the rate of 30% of the Face Value of Rs. 5/- each, amounting to Rs. 1.50/- per equity share for the financial year 2025-26, pending shareholder approval at the Annual General Meeting.
The Board also approved professional appointments for the coming year:
- M/s. JCR & Co. LLP, Chartered Accountants, were appointed as the Internal Auditors for the financial year 2026-27.
- M/s. V.J. Talati & Co., Cost Accountants, were re-appointed as the Cost Auditors for the financial year 2026-27.
Financial Performance Highlights
The Company's audited financial results for the quarter and financial year ended March 31, 2026, show the following key figures (in Rs. Lakhs, except for Earnings Per Share):| Particulars | Ended 31 March 2026 | Ended 31 Dec 2025 |
|---|---|---|
| Revenue from operations | 15,305.75 | 16,122.27 |
| Other Income | 295.62 | 1,357.16 |
| Total Income | 15,601.37 | 16,286.98 |
| Total Expenses | 14,357.59 | 15,632.21 |
| Profit/ (Loss) after Tax from Continuing Operations | (1,941.28) | 1,610.09 |
| Total Comprehensive Income | (2,280.20) | 1,586.09 |
Operational and Corporate Developments
In terms of operational updates, the Company revealed that it reversed income amounting to Rs. 3,324.66 lakhs in the quarter ended March 31, 2026. This reversal was attributed to difficulties meeting committed timelines by a customer for technical know-how usage in the Middle East region due to ongoing regional instability.On a corporate front, Bajaj Healthcare Limited confirmed the acquisition of Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis. This acquisition was completed on April 7, 2025, for a total consideration of Rs. 1,085 lakhs.
Financial Statements Summary
The audited financial reports for the year ended March 31, 2026, showed significant changes in assets and liabilities compared to the previous year.Balance Sheet Highlights (Rs. in Lakhs)
| Particulars | As at 31 Mar 2026 (Audited) | As at 31 Mar 2025 (Audited) |
|---|---|---|
| Total Non-Current Assets | 1,065.01 | 1,889.52 |
| Total Current Assets | 7,600.48 | 3,460.22 |
| Total Assets | 92,321.72 | 83,304.62 |
| Total Equity | 51,617.10 | 45,037.26 |
| Total Equity and Liabilities | 39,021.49 | 36,688.20 |
Cash Flow Summary (Rs. in Lakhs)
| Particulars | As at 31 March 2026 (Audited) | As at 31 March 2025 (Audited) |
|---|---|---|
| Net Cash from Operating activities (A) | 5,808.13 | 2,162.05 |
| Net Cash used in Investing activities (B) | (4,777.95) | (1,481.51) |
| Net Cash from Financing activities (C) | 2,432.98 | (637.63) |
| Net increase in Cash & Cash Equivalents (A+B+C) | 3,463.16 | 42.91 |
BAJAJHCARE Stock Price Movement
Bajaj Healthcare Limited shares slipped 0.37% on Friday, settling at ₹336.55 following an intraday drop of ₹1.25. The stock finished trading with a total volume of 416,278 shares recorded throughout the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.